Race Oncology Ltd (ASX:RAC) Share Price

Company Profile

Business description
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.
Contact
1 Macquarie Place
Level 36, Gateway
SydneyNSW2000
AUS
T: +61 280513043
https://www.raceoncology.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees

Recommended

Find out how this defensive player has fared after earnings.

Simonelle Mody | 03 September 2025

No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.

Brian Colello, CPA | 03 September 2025

Cost reductions lower our profit estimates but should lead to improved long-term outcomes.

Angus Hewitt, CFA | 03 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,091.40	51.20	0.57%
CAC 40	7,694.20	25.51	-0.33%
DAX 40	23,766.83	172.03	0.73%
Dow JONES (US)	45,283.16	11.93	0.03%
FTSE 100	9,217.81	39.82	0.43%
HKSE	25,058.51	284.92	-1.12%
NASDAQ	21,501.18	3.45	0.02%
Nikkei 225	42,580.27	641.38	1.53%
NZX 50 Index	13,133.20	58.39	0.45%
S&P 500	6,453.13	4.87	0.08%
S&P/ASX 200	8,826.50	59.20	0.68%
SSE Composite Index	3,765.88	47.68	-1.25%